Publications by authors named "Mari Rose Aplasca-De Los Reyes"
Article Synopsis
- The study aimed to compare the immunogenicity, safety, and effectiveness of an MF59-adjuvanted trivalent influenza vaccine (aTIV) with a non-adjuvanted vaccine (TIV) in individuals aged 65 and older.
- Over 7,000 participants received either aTIV or TIV, and results showed that aTIV produced significantly higher antibody responses than TIV after 22 days, although it did not meet all criteria for superiority.
- While aTIV caused slightly more mild to moderate side effects, it demonstrated a potential advantage in boosting immune responses in elderly patients, particularly against A/H3N2 influenza strains.
Immunogenicity and safety of ACWY-TT compared with licensed ACWY polysaccharide vaccine (MenPS) in healthy adults, and lot-to-lot consistency of three ACWY-TT lots were evaluated in a phase 3, open, controlled study. Adults aged 18-55 y were randomized to receive ACWY-TT (one of three lots) or MenPS. Serum bactericidal antibodies (rSBA) were measured pre- and 1 mo post-vaccination.
View Article and Find Full Text PDFCo-administration of meningococcal serogroups A, C, W-135 and Y conjugate vaccine (ACWY-TT) with seasonal influenza vaccine was investigated in a subset of adults enrolled in a larger study evaluating lot-to-lot consistency of ACWY-TT and non-inferiority to licensed tetravalent meningococcal polysaccharide vaccine (MenPS). Subjects in this sub-study were randomized (3:1:1) to receive ACWY-TT alone (ACWY-TT group) or with seasonal influenza vaccine (Coad), or licensed MenPS alone. Serum bactericidal antibodies (rSBA) and serum haemagglutination-inhibition (HI) antibody titers were measured pre- and 1 mo post-vaccination.
View Article and Find Full Text PDF